Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

1. Joint United Nations Programme on HIV/AIDS (2013) Global report: UNAIDS report on the global AIDS epidemic 2013. http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf. Accessed 1 March 2015.

2. Chi BH, Bolton-Moore C, Holmes CB (2013) Prevention of mother-to-child HIV transmission within the continuum of maternal, newborn, and child health services. Curr Opin HIV AIDS 8: 498–503. doi: 10.1097/COH.0b013e3283637f7a 23872611

3. Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, et al. (2012) HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 9: e1001245. doi: 10.1371/journal.pmed.1001245 22802730

4. Bor J, Herbst AJ, Newell ML, Bärnighausen T (2013) Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 339: 961–965. doi: 10.1126/science.1230413 23430655

5. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML (2013) High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 339: 966–971. doi: 10.1126/science.1228160 23430656

6. Holmes CB, Coggin W, Jamieson D, Mihm H, Granich R, et al. (2010) Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA 304: 313–320. doi: 10.1001/jama.2010.993 20639565

7. Medecins Sans Frontieres (2013) Untangling the web of antiretroviral price reductions 2013. http://www.msfaccess.org/content/untangling-web-antiretroviral-price-reductions. Accessed 1 March 2015.

8. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM (2010) Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 10: 155–166. doi: 10.1016/S1473-3099(09)70328-7 20185094

9. McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR (2013) Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bull World Health Organ 91: 377–85E. doi: 10.2471/BLT.12.112946 23678201

10. Aghokeng AF, Monleau M, Eymard-Duvernay S, Dagnra A, Kania D, et al. (2014) Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-Saharan Africa and southeast Asia. Clin Infect Dis 58: 99–109. doi: 10.1093/cid/cit627 24076968

11. HIV/AIDS Programme World Health Organization (2012) WHO HIV drug resistance report 2012. http://www.who.int/hiv/pub/drugresistance/report2012/en/. Accessed 1 March 2015.

12. Stadeli KM, Richman DD (2013) Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther 18: 115–123. doi: 10.3851/IMP2437 23052978

13. Frentz D, Boucher CA, van de Vijver DA (2012) Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 14: 17–27. 22297501

14. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, et al. (2012) Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 380: 1250–1258. doi: 10.1016/S0140-6736(12)61038-1 22828485

15. Hamers RL, Schuurman R, Sigaloff KC, Wallis CL, Kityo C, et al. (2012) Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 12: 307–317. doi: 10.1016/S1473-3099(11)70255-9 22036233

16. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA 3rd, et al. (2008) Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 197: 867–870. doi: 10.1086/528802 18269317

17. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, et al. (2012) Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 26: 185–192. doi: 10.1097/QAD.0b013e32834e9d7d 22179227

18. Mollan K, Daar ES, Sax PE, Balamane M, Collier AC, et al. (2012) HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. J Infect Dis 206: 1920–1930. doi: 10.1093/infdis/jis613 23148287

19. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, et al. (2011) Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 11: 363–371. doi: 10.1016/S1473-3099(11)70032-9 21354861

20. Chung MH, Beck IA, Dross S, Tapia K, Kiarie JN, et al. (2014) Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya. J Acquir Immune Defic Syndr 67: 246–253. doi: 10.1097/QAI.0000000000000312 25140907

21. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 4: e4724. doi: 10.1371/journal.pone.0004724 19266092

22. Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W (2001) Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci U S A 98: 13907–13912. 11698656

23. Yerly S, Rakik A, De Loes SK, Hirschel B, Descamps D, et al. (1998) Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol 72: 3520–3523. 9557630

24. Gifford RJ, Liu TF, Rhee SY, Kiuchi M, Hue S, et al. (2009) The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 25: 1197–1198. doi: 10.1093/bioinformatics/btp134 19304876

25. Pineda-Pena AC, Faria NR, Imbrechts S, Libin P, Abecasis AB, et al. (2013) Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol 19: 337–348. doi: 10.1016/j.meegid.2013.04.032 23660484

26. Kouyos RD, von Wyl V, Yerly S, Boni J, Rieder P, et al. (2011) Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin Infect Dis 52: 532–539. doi: 10.1093/cid/ciq164 21220770

27. Ragonnet-Cronin M, Aris-Brosou S, Joanisse I, Merks H, Vallee D, et al. (2012) Genetic diversity as a marker for timing infection in HIV-infected patients: evaluation of a 6-month window and comparison with BED. J Infect Dis 206: 756–764. doi: 10.1093/infdis/jis411 22826337

28. Andersson E, Shao W, Bontell I, Cham F, Cuong do D, et al. (2013) Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. Infect Genet Evol 18: 125–131. doi: 10.1016/j.meegid.2013.03.050 23583545

29. Lambert PC, Sutton AJ, Abrams KR, Jones DR (2002) A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol 55: 86–94. 11781126

30. Bates D, Maechler M, Bolker B, Walker S (2015) Package ‘Ime4’. http://cran.r-project.org/web/packages/lme4/lme4.pdf. Accessed 1 March 2015.

31. Tang MW, Liu TF, Shafer RW (2012) The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology 55: 98–101. doi: 10.1159/000331998 22286876

32. Paradis E, Claude J, Strimmer K (2004) APE: analyses of phylogenetics and evolution in R language. Bioinformatics 20: 289–290. 14734327

33. Drummond AJ, Rambaut A (2007) BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol 7: 214. 17996036

34. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, et al. (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31: 298–303. 12520007

35. Sluis-Cremer N, Jordan MR, Huber K, Wallis CL, Bertagnolio S, et al. (2014) E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings. Antiviral Res 107C: 31–34.

36. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF (2008) Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 13 (Suppl 2): 25–36. 18575189

37. Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, et al. (2011) Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 203: 1174–1181. doi: 10.1093/infdis/jiq167 21451005

38. Castro H, Pillay D, Cane P, Asboe D, Cambiano V, et al. (2013) Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis 208: 1459–1463. doi: 10.1093/infdis/jit345 23904291

39. Cambiano V, Bertagnolio S, Jordan MR, Pillay D, Perriens JH, et al. (2014) Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation. AIDS 28 (Suppl 1): S15–S23. doi: 10.1097/QAD.0000000000000082 24468943

40. Hue S, Gifford RJ, Dunn D, Fernhill E, Pillay D, et al. (2009) Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol 83: 2645–2654. doi: 10.1128/JVI.01556-08 19158238

41. Antoniadou ZA, Kousiappa I, Skoura L, Pilalas D, Metallidis S, et al. (2013) Short communcation: molecular epidemiology of HIV type 1 infection in northern Greece (2009–2010): evidence of a transmission cluster of HIV type 1 subtype a1 drug-resistant strains among men who have sex with men. AIDS Res Hum Retroviruses 30: 225–232. doi: 10.1089/AID.2013.0166 24059291

42. Lindstrom A, Ohlis A, Huigen M, Nijhuis M, Berglund T, et al. (2006) HIV-1 transmission cluster with M41L ‘singleton’ mutation and decreased transmission of resistance in newly diagnosed Swedish homosexual men. Antivir Ther 11: 1031–1039. 17302373

43. Borroto-Esoda K, Waters JM, Bae AS, Harris JL, Hinkle JE, et al. (2007) Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. AIDS Res Hum Retroviruses 23: 988–995. 17725415

44. Lee GQ, Bangsberg DR, Muzoora C, Boum Y, Oyugi JH, et al. (2014) Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda. AIDS Res Hum Retroviruses 30: 896–906. doi: 10.1089/AID.2014.0043 24960249

45. Phillips AN, Cambiano V, Miners A, Revill P, Pillay D, et al. (2014) Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis. Lancet HIV 1: e85–e93.

46. Zhang G, Cai F, Zhou Z, DeVos J, Wagar N, et al. (2013) Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay. J Clin Microbiol 51: 3666–3674. doi: 10.1128/JCM.01669-13 23985909

47. Ellis GM, Vlaskin TA, Koth A, Vaz LE, Dross SE, et al. (2013) Simultaneous and sensitive detection of human immunodeficiency virus type 1 (HIV) drug resistant genotypes by multiplex oligonucleotide ligation assay. J Virol Methods 192: 39–43. doi: 10.1016/j.jviromet.2011.11.030 23660583

48. HIV/AIDS Programme World Health Organization (2014) Surveillance of HIV drug resistance in adults initiating antiretroviral therapy (pre-treatment HIV drug resistance). http://www.who.int/hiv/pub/drugresistance/pretreatment_drugresistance/en/. Accessed 1 March 2015.

49. Barnhart M, Shelton JD (2015) ARVs: the next generation. Going boldly together to new frontiers of HIV treatment. Glob Health Sci Pract. Epub ahead of print.